This is a rollover study designed to investigate the safety and effectiveness of investigational study drug ARRY-371797 in patients who previously received ARRY-371797 in a study for patients with LMNA-related dilated cardiomyopathy sponsored by Array BioPharma and may, in the Investigator's opinion, derive benefit from continued treatment.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
Timeframe: Baseline up to 30 days after last dose of study drug (i.e., maximum up to 282 weeks)
Number of Participants With Change From Baseline Value in Clinical Laboratory Hematology Test Results to Worst Value
Timeframe: Baseline, Post-Baseline (anytime from first dose of study drug to maximum duration of up to 282 weeks)
Number of Participants With Change From Baseline Value in Clinical Laboratory Chemistry Test Results to Worst Value
Timeframe: Baseline, Post-Baseline (anytime from first dose of study drug to maximum duration of up to 282 weeks)
Number of Participants With Abnormal Physical Examination Findings
Timeframe: Baseline up to 30 days after last dose of study drug (i.e., maximum up to 282 weeks)
Number of Participants With Abnormalities in Vital Signs
Timeframe: Baseline up to 30 days after last dose of study drug (i.e., maximum up to 282 weeks)
Number of Participants With Abnormal 12-lead Electrocardiogram (ECG) Findings
Timeframe: Baseline up to 30 days after last dose of study drug (i.e., maximum up to 282 weeks)